
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Pharmacol. , 13 March 2024
Sec. Inflammation Pharmacology
Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1382529
This article is a correction to:
Unveiling the therapeutic potential of exogenous β-hydroxybutyrate for chronic colitis in rats: novel insights on autophagy, apoptosis, and pyroptosis
A Corrigendum on
Unveiling the therapeutic potential of exogenous β-hydroxybutyrate for chronic colitis in rats: novel insights on autophagy, apoptosis, and pyroptosis
by Abdelhady R, Saber S, Ahmed Abdel-Reheim M, Mohammad S. Alamri M, Alfaifi J, I. E. Adam M, A. Saleh L, I. Farag A, A. Elmorsy E, S. El-Wakeel H, S. Doghish A, E. Shaker M, H. Hazem S, A. Ramadan H, S. Hamad R and A. Mohammed O (2023). Front. Pharmacol. 14:1239025. doi: 10.3389/fphar.2023.1239025
In the published article, there was an error in affiliations 11 and 12. Instead of:
“11Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.”
“12Pharmacology and Therapeutics Department, Qassim College of Medicine, Qassim University, Buraydah, Saudi Arabia.”
it should be:
“11Department of Pharmacology and Therapeutics, Qassim College of Medicine, Qassim University, Buraydah, Saudi Arabia.”
“12Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: ulcerative colitis, β-hydroxybutyrate, NLRP3 inflammasome, apoptosis, pyroptosis
Citation: Abdelhady R, Saber S, Abdel-Reheim MA, Mohammad S. Alamri M, Alfaifi J, Adam MIE, Saleh LA, Farag AI, Elmorsy EA, El-Wakeel HS, Doghish AS, Shaker ME, Hazem SH, Ramadan HA, Hamad RS and Mohammed OA (2024) Corrigendum: Unveiling the therapeutic potential of exogenous β-hydroxybutyrate for chronic colitis in rats: novel insights on autophagy, apoptosis, and pyroptosis. Front. Pharmacol. 15:1382529. doi: 10.3389/fphar.2024.1382529
Received: 05 February 2024; Accepted: 07 February 2024;
Published: 13 March 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Abdelhady, Saber, Abdel-Reheim, Mohammad S. Alamri, Alfaifi, Adam, Saleh, Farag, Elmorsy, El-Wakeel, Doghish, Shaker, Hazem, Ramadan, Hamad and Mohammed. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sameh Saber, c2FtcGhhcm04MUBnbWFpbC5jb20=; Mustafa Ahmed Abdel-Reheim, bS5haG1lZEBzdS5lZHUuc2E=; Osama A. Mohammed, b2Ftb2hhbWVkQHViLmVkdS5zYQ==
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.